Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences develops proprietary oncology drugs built around its Phospholipid Drug Conjugate™ (PDC) delivery platform. News about CLRB commonly centers on targeted radiotherapeutic programs, including iopofosine I 131 for Waldenström macroglobulinemia and CLR 121125, also called CLR 125, an iodine-125 Auger-emitting program for solid tumors such as triple negative breast, lung and colorectal cancers.
Company updates also cover clinical data from the CLOVER WaM study, oncology conference presentations, European and U.S. regulatory interactions, intellectual property protection, securities financings, and periodic financial results with corporate updates. The recurring disclosures reflect a late-stage clinical biopharmaceutical company funding and advancing cancer-cell-targeting treatments through internal development and research collaborations.
Cellectar Biosciences (NASDAQ: CLRB) announced participation in a fireside chat at the H.C. Wainwright Bioconnect conference, scheduled for January 10-13, 2022. CEO Jim Caruso and CBO Jarrod Longcor will discuss company updates, with the chat available on-demand from 7:00 am ET on January 10.
Cellectar is focused on developing targeted cancer therapies, leveraging its proprietary Phospholipid Drug Conjugate™ (PDC) platform. The pipeline includes iopofosine for relapsed or refractory cancers, currently in pivotal studies.
Cellectar Biosciences (NASDAQ: CLRB) presented promising data from 11 patients in its ongoing Phase 2 CLOVER-1 study of iopofosine I-131 for treating refractory multiple myeloma at the ASH Annual Meeting. The trial showed an overall response rate (ORR) of 45.5%, with a clinical benefit rate (CBR) of 72.7% and a disease control rate (DCR) of 100%. In a subgroup of quad/penta drug refractory patients, the ORR reached 80%.
Despite these positive results, cytopenias were noted as the primary adverse events. The company anticipates sharing further data as the study progresses.
On December 8, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced a poster presentation at the ASH Annual Meeting, showcasing data from the ongoing Phase 2 CLOVER-1 study of iopofosine I-131. The study focuses on eleven patients with triple-class refractory multiple myeloma, highlighting preliminary efficacy and safety results. The poster session will occur on December 11, 2021. Iopofosine is designed for targeted cancer treatment and is undergoing multiple clinical studies, including a pivotal trial for Waldenstrom's macroglobulinemia.
Cellectar Biosciences (CLRB) announced positive results from a Phase 1 study of iopofosine I-131 for treating pediatric relapsed cancers, specifically high-grade gliomas and soft tissue sarcomas. The study showed promising tumor responses, with patients experiencing over 5 months of progression-free survival, almost double the historical norm of 2-3 months. The Data Monitoring Committee has approved dose escalations, suggesting the treatment is safe and tolerable. Cellectar plans to engage with the FDA on potential next steps for regulatory approval.
Cellectar Biosciences (NASDAQ: CLRB) reported Q3 financial results for the period ending September 30, 2021. The company completed Part A of a safety study for iopofosine in combination with external beam radiation for head and neck cancer. Preliminary data indicates safety and tolerability. They secured a $2 million NIH Phase II SBIR grant to support iopofosine’s pivotal study in Waldenstrom’s macroglobulinemia. Cash reserves stood at $40.3 million, but the company posted a net loss of $5.8 million for Q3, widening from a $3.9 million loss in 2020.
Cellectar Biosciences (NASDAQ: CLRB) announced Dr. Laurence Reilly as interim chief medical officer, succeeding Dr. John Friend, who departs for personal reasons. Dr. Reilly brings extensive experience in hematological oncology and is expected to lead Cellectar's clinical development programs, including the pivotal trial for iopofosine I-131 in treating Waldenstrom’s macroglobulinemia. The company remains financially stable and aims to advance its cancer treatment pipeline through ongoing trials and collaborations.
Cellectar Biosciences (NASDAQ: CLRB) has announced a collaboration with BBK Worldwide to enhance patient support services for participants in its clinical studies. This initiative aims to provide comprehensive concierge services, including transportation and assistance with reimbursement for cancer patients. The focal point of this collaboration is the ongoing pivotal study of iopofosine I-131 for Waldenstrom's macroglobulinemia. Cellectar is also engaged in additional clinical studies involving iopofosine for other hematologic malignancies.
Cellectar Biosciences (NASDAQ: CLRB) announced the initiation of an expansion cohort for the iopofosine I-131 study in patients with relapsed or refractory head and neck cancer. Following the completion of a safety phase, the University of Wisconsin will assess the potential of iopofosine combined with external beam radiation therapy (EBRT) to reduce radiation doses while maintaining tumor response. The study aims to enroll up to 24 patients and is part of a broader evaluation of iopofosine in various cancers. The company remains optimistic about the treatment's efficacy and safety.
On September 15, 2021, Cellectar Biosciences (NASDAQ: CLRB) announced that CEO James Caruso will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, 2021, at 12:25 PM ET. The presentation will provide a company overview, highlighting its focus on developing targeted cancer therapies using its proprietary Phospholipid Drug Conjugate™ platform. Cellectar is currently conducting a pivotal Phase 2 study for its lead candidate, iopofosine, aimed at providing targeted delivery of iodine-131 for cancer treatment.
Cellectar Biosciences (NASDAQ: CLRB) announced a significant achievement on August 18, 2021, securing a $2 million Phase II NIH Small Business Innovation Research grant from the National Cancer Institute. This funding will bolster the ongoing pivotal study of iopofosine I-131 in treating Waldenstrom’s macroglobulinemia, which began in January 2021 and aims for full enrollment within 18 months. With over $46.8 million in cash equivalents reported as of June 30, 2021, the company is projected to sustain operations into Q3 2023, covering top-line data and NDA submission.